Researchers have found that AML cells have a large amount of a protein called CD47. This protein can protect the cancer cells by preventing the body’s immune system removing and destroying them.
Hu5F9-G4 is a type of biological therapy called a monoclonal antibody. It works by blocking the signals of CD47 that protect the AML cells. Early studies have shown that Hu5F9-G4 can successfully eliminate AML cells in laboratory experiments, so researchers now want to see if Hu5F9-G4 can help treat people with AML.
The aims of this trial are to:
- Find out how well Hu5F9-G4 works for people with AML
- See how safe it is
- Find the best dose of Hu5F9-G4
- See what the side effects are
- How Hu5F9-G4 works in the body
You may be eligible to join this trial if:
- You have AML that has come back after treatment, or has continued to get worse during treatment
- You are 18 years of age or older